Plain-English translation of NCT06640348 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are testing a new type of blood test chip — called a SERS platform — that can detect ovarian cancer by looking for special markers in your blood. The chip analyzes unique patterns in blood samples to help doctors identify ovarian cancer earlier and more accurately than current methods. If successful, this test could become a helpful screening tool for women at risk.
Ovarian cancer is often detected late because there isn't a reliable early screening test. This trial exists to see whether the new blood test can accurately identify ovarian cancer in its earlier stages, when treatment may be more effective.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have one or more blood samples drawn so researchers can analyze them using the new SERS chip technology. The study compares blood patterns from ovarian cancer patients with patterns from healthy volunteers to teach the test how to recognize cancer. Your participation helps build the foundation for this new diagnostic tool — there is no medication to take or lengthy treatment involved.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Sponsor
Anhui Provincial Hospital
Enrollment target
~70 participants
Started
January 2025
Primary completion
December 2027
Age range
18 Years – 70 Years
Sex
Female only
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ying Zhou, MD
Anhui Provincial Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.